Selective estrogen receptor modulator

Tamoxifen (Nolvadex)

Tamoxifen (Nolvadex) is an oral nonsteroidal antiestrogen. Its US label gives a terminal half-life of about 5 to 7 days and a peak about 5 hours after a single 20 mg dose.1

Strong evidenceGet the app

Level after one dose

Tamoxifen (Nolvadex) after one dose: 50% at ~14 days, 25% at 28 days, 12.5% at 42 days.

Drawn from the half-life in the app's model, ~14 days. The model's figures

Tamoxifen citrate is described in its US prescribing information as a nonsteroidal antiestrogen for oral administration.1 Nolvadex is a tamoxifen product: the ATLAS trial investigators describe the tamoxifen regimen in their trial as "almost always Nolvadex 20 mg per day".2

The label states that tamoxifen citrate tablets are "effective in the treatment of metastatic breast cancer in women and men" and are indicated to reduce the incidence of breast cancer in women at high risk for breast cancer.1 For metastatic disease it adds that patients whose tumors are estrogen receptor positive are more likely to benefit.1 Its boxed warning names uterine malignancies, stroke and pulmonary embolism as serious and life-threatening events in the risk reduction setting.1

The NSABP P-1 and ATLAS trials, described below, enrolled women.3,2 Wibowo and colleagues, Andrology, 2016, write that "Tamoxifen is an off-label option to treat men for breast cancer, infertility, and idiopathic gynecomastia".4 In 2014 Rahnema and colleagues, Fertility and Sterility, reviewed hypogonadal men with a history of anabolic-androgenic steroid use; their summary lists selective estrogen receptor modulators among management strategies and states: "Intended as a meta-analysis, but no quality studies met the inclusion criteria".5

2

How it works

In animals and test systems

The label states that tamoxifen "has demonstrated potent antiestrogenic properties in animal test systems" and that its antiestrogenic effects "may be related to its ability to compete with estrogen for binding sites in target tissues such as breast".1 In a rat model of dimethylbenzanthracene-induced mammary carcinoma, the label states that tamoxifen appears to exert its antitumor effects by binding the estrogen receptors.1

In human samples and in men

In cytosols derived from human breast adenocarcinomas, the label reports that tamoxifen competes with estradiol for estrogen receptor protein.1 In the 2010 crossover study in healthy men by Birzniece and colleagues, the authors describe tamoxifen as a SERM that "possesses central estrogen antagonistic effect but peripheral hepatic agonist effect, lowering IGF-I", and note that in men "the stimulation of GH and inhibition of LH secretion by testosterone requires aromatization to estradiol".6

3

Pharmacokinetics

Values from the Milligram app's model.

Half-life
~14 days
Bioavailability
95%
Typical dose
5–30 mg/day
Route
Oral
Time to peak
~5 h

The label gives a terminal elimination half-life of about 5 to 7 days for tamoxifen, with the plasma decline described as biphasic.1 The app's figure of about 14 days (336 hours) matches the label's figure for the metabolite N-desmethyl tamoxifen, not the label's terminal half-life for tamoxifen itself.1

Table 3.1Pharmacokinetics6 rows
ParameterValueNote
Half-life~14 days (336 hours) in the appThe label gives a terminal elimination half-life of about 5 to 7 days for tamoxifen, and about 14 days for N-desmethyl tamoxifen, estimated from steady-state concentrations reached in about 8 weeks.1
Bioavailability (oral)~95% in the appThe label gives no oral bioavailability figure; it reports a steady-state crossover study in which one 20 mg tablet once daily was bioequivalent to 10 mg tablets twice daily.1
Time to peak~5 hours in the appThe label reports an average peak plasma concentration of 40 ng/mL (range 35 to 45 ng/mL) approximately 5 hours after a single oral 20 mg dose, which matches the app's figure.1
Typical dose5–30 mg/day in the appThe label gives a daily dose of 20 to 40 mg for patients with breast cancer, and the trials in the dose table below used 10 to 20 mg a day.1
Steady stateAbout 4 weeks (tamoxifen), about 8 weeks (N-desmethyl tamoxifen)After 20 mg once daily for 3 months, average steady-state concentrations were 122 ng/mL (range 71 to 183) for tamoxifen and 353 ng/mL (range 152 to 706) for N-desmethyl tamoxifen.1
Metabolism and excretionNot in the appThe label names N-desmethyl tamoxifen as the major plasma metabolite, tamoxifen as a substrate of cytochrome P-450 3A, 2C9 and 2D6, and about 65% of a 20 mg dose excreted over 2 weeks, mainly in feces.1

The label describes its excretion study as being in women, and it states that "The effects of age, gender and race on the pharmacokinetics of tamoxifen have not been determined".1 The chart below uses the app's half-life of 14 days and time to peak of 5 hours, as an illustration, and its daily interval is the one the label's steady-state data and the NSABP P-1 trial used.1,3

Level over 6 weeks

Interval between doses

Level, as a share of the peak after one 20 mg dose

As studied: every day1.

An illustration from a pharmacokinetic model using a half-life of 336 hours (14 days). It is not a measured level or a suggested dose.

4

Human studies

The largest single trials cited here are breast cancer prevention and adjuvant trials in women: 13,388 women in NSABP P-1 and 12,894 in ATLAS, and the patient-level meta-analysis below pooled 21,457 women.3,2,8 The studies of hormone effects in men cited here enrolled 10 men and 120 men.6,7

Table 4.1Human studies6 rows
Study and yearDesignPeopleDose and lengthMain result
Fisher and colleagues, 19983Randomised, placebo-controlled prevention trial (NSABP P-1)313,388 women at increased risk for breast cancer (placebo n=6,707, tamoxifen n=6,681)320 mg/day for 5 years3Invasive breast cancer risk reduced by 49% (two-sided P<.00001); endometrial cancer risk ratio 2.53 (95% CI 1.35-4.97); stroke, pulmonary embolism and deep-vein thrombosis rates elevated (label: stroke RR 1.42, 95% CI 0.82-2.51; deep-vein thrombosis RR 1.59, 0.86-2.98); ischemic heart disease rate not altered.3,1
Early Breast Cancer Trialists' Collaborative Group, 20118Patient-level meta-analysis of 20 trials of about 5 years of tamoxifen versus none821,457 women with early breast cancer, 10,645 with ER-positive disease8About 5 years of tamoxifen, about 80% compliance8ER-positive disease: recurrence rate ratio 0.53 (SE 0.03) in years 0-4, 0.68 (0.06) in years 5-9, 0.97 (0.10) in years 10-14; ER-negative: little or no effect.8
Davies and colleagues (ATLAS), 20132Randomised trial with open control (no placebo): continue tamoxifen or stop212,894 women who had completed 5 years of tamoxifen; 6,846 with ER-positive disease in the breast cancer analyses2Continue tamoxifen to 10 years or stop at 5 years2ER-positive disease: 617 recurrences in 3,428 women continuing vs 711 in 3,418 controls (p=0.002); pulmonary embolus rate ratio 1.87 (95% CI 1.13-3.07) and endometrial cancer 1.74 (1.30-2.34) among all women.2
Birzniece and colleagues, 20106Randomised, open-label crossover of tamoxifen and raloxifene610 healthy men6Tamoxifen 10 and 20 mg/d (and raloxifene 60 and 120 mg/d), 2 weeks each, with a 2-week washout6Tamoxifen, but not raloxifene, reduced IGF-I by 25±6% (P<0.01) and increased SHBG by 20±7% (P<0.05) at the higher dose; both drugs raised LH, FSH and testosterone; the GH response to arginine showed a nonstatistically significant trend downward with both.6
Kadioglu, 20097Retrospective study7120 normogonadotropic infertile men with idiopathic oligozoospermia720 mg daily as a single dose for 6 months7FSH, luteinizing hormone and testosterone levels were significantly increased; sperm count rose more in men with lower starting FSH.7
Khashaba and colleagues, 20259Systematic review and meta-analysis of 10 randomised trials of clomiphene or tamoxifen9Men with idiopathic male subfertility9Not given in the review's summary9Clomiphene and placebo pregnancy rates were 10.4% and 7.1% (odds ratio 1.30, 95% CI 0.27-6.17, p=0.74); no meta-analysis could be calculated for tamoxifen versus placebo.9

Deeper analysis: NSABP P-1

Fisher and colleagues of the National Surgical Adjuvant Breast and Bowel Project reported the P-1 Breast Cancer Prevention Trial in the Journal of the National Cancer Institute in 1998.3 It randomly assigned 13,388 women at increased risk (aged 60 or older, or 35 to 59 with a 5-year predicted risk of at least 1.66%, or with lobular carcinoma in situ) to placebo (n=6,707) or 20 mg/day tamoxifen (n=6,681) for 5 years.3

Tamoxifen reduced the risk of invasive breast cancer by 49% (two-sided P<.00001), with cumulative incidence through 69 months of 43.4 versus 22.0 per 1,000 women in the placebo and tamoxifen groups, and reduced the risk of noninvasive breast cancer by 50% (two-sided P<.002).3 Estrogen receptor-positive tumors were reduced by 69%, with no difference in the occurrence of estrogen receptor-negative tumors.3

Harms were reported in the same publication: endometrial cancer rose (risk ratio 2.53; 95% CI 1.35-4.97), all endometrial cancers in the tamoxifen group were stage I with no endometrial cancer deaths, and stroke, pulmonary embolism and deep-vein thrombosis rates were elevated, more often in women aged 50 or older.3 In the label's account of the same trial, the stroke increase (RR 1.42, 95% CI 0.82-2.51) is described as "non-statistically significant".1 The publication also reports a reduction in hip, radius (Colles') and spine fractures; the label's account gives 9 hip fractures on tamoxifen against 20 on placebo, a non-significant reduction, and 69 wrist fractures against 74.3,1 The label's account of the same trial also states that "there was no impact of tamoxifen on overall or breast cancer-related mortality", that 25 percent of participants received the drug for 5 years, and that "The longer-term effects are not known".1 The label adds that two European prevention trials, smaller than P-1 and enrolling women at lower risk, "showed no difference in the number of breast cancer cases between the tamoxifen and placebo arms".1

The record lists research grants U10-CA-37377 and U10-CA-69974 from the US National Cancer Institute; it names no company funder and states no ties of the authors to one.3 The published summary states no limitations of its own.3

Deeper analysis: ATLAS

Davies and colleagues of the Clinical Trial Service Unit, University of Oxford, and the ATLAS Collaborative Group reported the Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) trial in The Lancet in 2013.2 In the trial, 12,894 women with early breast cancer who had completed 5 years of tamoxifen were randomly allocated to continue to 10 years or stop at 5 years (open control), entering between 1996 and 2005.2 Breast cancer outcomes are reported for the 6,846 women with ER-positive disease and side-effects for all women.2

Among women with ER-positive disease, continuing tamoxifen was followed by fewer recurrences (617 in 3,428 women vs 711 in 3,418 controls, p=0.002), fewer breast cancer deaths (331 vs 397, p=0.01) and fewer deaths overall (639 vs 722, p=0.01).2 The recurrence rate ratio was 0.90 (95% CI 0.79-1.02) in years 5 to 9 and 0.75 (0.62-0.90) in later years, and breast cancer mortality rate ratios were 0.97 (0.79-1.18) and 0.71 (0.58-0.88).2 Treatment allocation "seemed to have no effect on breast cancer outcome among 1248 women with ER-negative disease".2

Among all 12,894 women, deaths without recurrence from causes other than breast cancer were 691 in 6,454 women allocated to continue vs 679 in 6,440 controls (RR 0.99, 0.89-1.10; p=0.84).2 Incidence rate ratios were 1.87 for pulmonary embolus (95% CI 1.13-3.07, including 0.2% mortality in both groups), 1.06 for stroke (0.83-1.36), 0.76 for ischaemic heart disease (0.60-0.95) and 1.74 for endometrial cancer (1.30-2.34).2 The authors write that the apparent reduction in ATLAS "might be largely a chance finding", noting that no significant protection against heart disease was seen in trials of tamoxifen versus no tamoxifen.2 The cumulative risk of endometrial cancer during years 5 to 14 was 3.1% (mortality 0.4%) for women allocated to continue versus 1.6% (mortality 0.2%) for controls.2

The trial's listed funders were Cancer Research UK, UK Medical Research Council, AstraZeneca UK, US Army and EU-Biomed, and Oxford University was the trial sponsor.2 The authors state that the study was "designed, conducted, analysed, interpreted and reported by the investigators independently of all funding bodies", and declare no conflicts of interest.2 The report states that no placebo was used among controls, and that at year 7 after diagnosis 84% of those allocated to continue were still on tamoxifen compared with 4% of controls, a difference of 80%.2

Deeper analysis: tamoxifen and raloxifene in healthy men

Birzniece and colleagues of the Garvan Institute of Medical Research and St. Vincent's Hospital, Sydney, published a randomised, open-label crossover study in the Journal of Clinical Endocrinology and Metabolism in 2010.6 Ten healthy men were randomized to 2-week sequential treatment with tamoxifen (10 and 20 mg/d) and raloxifene (60 and 120 mg/d), with a 2-week washout between.6 The GH response to arginine and circulating IGF-I, LH, FSH, testosterone and SHBG were measured.6

Tamoxifen, but not raloxifene, significantly reduced IGF-I by 25±6% (P<0.01) and increased SHBG by 20±7% (P<0.05) at the higher dose.6 Both SERMs significantly increased LH, FSH and testosterone, and the mean increase in testosterone (40 vs 25%; P<0.05) and LH (70 vs 30%; P<0.01) was greater with tamoxifen than with raloxifene.6 There was a nonstatistically significant trend toward a reduction in the GH response to arginine with both SERMs.6 The authors concluded that "in therapeutic doses, raloxifene perturbs the GH and gonadal axes to a lesser degree than tamoxifen".6

The study had 10 participants and each treatment period lasted 2 weeks; the published record names no funder, states no author ties to a sponsor and gives no limitations of its own, and lists its publication type as research support, non-US government.6

Other reports in men

Kadioglu, International Urology and Nephrology, 2009, retrospectively analysed 120 normogonadotropic infertile men with idiopathic oligozoospermia who each received 20 mg daily for 6 months, and the FSH, luteinizing hormone and testosterone levels were significantly increased afterwards.7 The author states that the results need confirmation in double-blind, placebo-controlled, randomized trials before firm conclusions can be drawn.7 Khashaba and colleagues, Asian Journal of Urology, 2025, searched MEDLINE, PubMed/PMC, EMBASE, CINAHL, CENTRAL, Scopus, Google Scholar and Web of Science, included ten randomised trials of clomiphene or tamoxifen, and wrote that "The effect of clomiphene citrate or tamoxifen on the pregnancy rate remains uncertain".9

The patient-level meta-analysis of 5 years of tamoxifen

The Early Breast Cancer Trialists' Collaborative Group (Davies, Godwin, Gray and colleagues), The Lancet, 2011, analysed individual patient data from 20 trials (n=21,457) of about 5 years of tamoxifen versus none, with about 80% compliance.8 In ER-positive disease (n=10,645) the recurrence rate ratio was 0.53 (SE 0.03) in years 0 to 4 and 0.68 (0.06) in years 5 to 9, and 0.97 (0.10) in years 10 to 14, "suggesting no further gain or loss after year 10".8 Breast cancer mortality was reduced by about a third throughout the first 15 years.8 Overall non-breast-cancer mortality was little affected, "despite small absolute increases in thromboembolic and uterine cancer mortality (both only in women older than 55 years)".8 In ER-positive disease the report counts nine deaths in the tamoxifen group versus one in the control group from uterus cancer, and six versus none from pulmonary embolus, in the first 5 years.8 The group is funded by Cancer Research UK, the British Heart Foundation and the Medical Research Council; it states that the sponsors had no role in design, data collection, analysis, interpretation or writing, and discloses that one author, MD, has received payment from AstraZeneca through grants to his department and for lectures and expert testimony.8

5

Doses reported in studies and on labels

Table 5.1Doses reported in studies and on labels6 rows
SourceDoseFrequencyLength
Label, patients with breast cancer120 to 40 mgDailyNot stated in that sentence
NSABP B-14, as described in the label110 mg tabletTwice a dayAt least 5 years
Fisher and colleagues, 1998 (NSABP P-1)320 mg/dayDaily5 years
Davies and colleagues, 2013 (ATLAS)2Nolvadex 20 mg per day (almost always)DailyTo 10 years, versus stopping at 5
Birzniece and colleagues, 2010610 and 20 mg/dDaily2 weeks each
Kadioglu, 2009720 mgOnce daily6 months

The app's typical dose is 5 to 30 mg a day; the label's statement for patients with breast cancer is 20 to 40 mg a day, and the studies above used 10 to 20 mg a day.1,6

6

Side effects reported

The label's account of NSABP P-1 counts 33 invasive endometrial cancers on tamoxifen against 14 on placebo (RR 2.48, 95% CI 1.27 to 4.92; the 1998 publication above gives 2.53, 1.35 to 4.97), 18 pulmonary embolism cases against 6 (RR 3.01, 1.15 to 9.27), 30 deep-vein thrombosis cases against 19 (RR 1.59, 0.86 to 2.98) and 34 strokes against 24 (RR 1.42, 0.82 to 2.51).1 Seven strokes were fatal (three on placebo, four on tamoxifen), and three pulmonary embolism cases in the tamoxifen group were fatal.1 Cataract surgery was performed in 201 women on tamoxifen and 129 on placebo, and the label lists ocular disturbances including corneal changes, decrement in color vision perception, retinal vein thrombosis and retinopathy among reports in patients receiving tamoxifen.1

In NSABP B-14, in women (tamoxifen n=1,422, placebo n=1,437), the label reports hot flashes in 64% against 48%, vaginal discharge in 30% against 15% and irregular menses in 25% against 19%, and states that all other adverse effects occurred with similar frequency.1 Thrombotic events were more frequent with tamoxifen (1.7% vs 0.4% through 5 years), and two of the patients treated with tamoxifen who had thrombotic events died.1 The label also states that some uterine malignancies have been fatal.1

In men with breast cancer, the label states that "Loss of libido and impotence have resulted in discontinuation of tamoxifen therapy in male patients" and that the safety profile in males is reported to be similar to that in women.1 Wibowo and colleagues, Andrology, 2016, who searched PubMed for randomised trials and also reviewed non-randomised reports, found that, excluding breast events, gastrointestinal and cardiovascular problems were the most commonly reported adverse events in men with prostate cancer, more psychiatric disorders were reported in men with breast cancer, and "Few AEs have been documented in men receiving tamoxifen for infertility and idiopathic gynecomastia".4 Less than 5% of men withdrew because of toxicity, most of those who discontinued were men with breast cancer, and cardiovascular events were the most common reason for stopping, though the reasons for withdrawal were unspecified in many cases.4

7

Bloodwork and markers

In the 10 healthy men studied by Birzniece and colleagues, 2-week tamoxifen at the higher dose lowered IGF-I by 25±6% and raised SHBG by 20±7%, and tamoxifen and raloxifene both raised LH, FSH and testosterone.6 The label reports that in oligospermic males treated with tamoxifen, "LH, FSH, testosterone and estrogen levels were elevated" and that "No significant clinical changes were reported".1

The label reports few grade 3 to 4 liver function changes in NSABP P-1 (10 on placebo and 6 on tamoxifen) and grade 3 to 4 platelet count drops in 6 women on tamoxifen and 2 on placebo.1 The label also states that tamoxifen "has been associated with changes in liver enzyme levels, and on rare occasions, a spectrum of more severe liver abnormalities including fatty liver, cholestasis, hepatitis and hepatic necrosis", that "A few of these serious cases included fatalities", and that in most reported cases the relationship to tamoxifen is uncertain.1

8

Regulatory and anti-doping status

The US label for tamoxifen citrate tablets lists indications in metastatic breast cancer in women and men (patients whose tumors are estrogen receptor positive are more likely to benefit), adjuvant treatment of node-positive and node-negative breast cancer in women, ductal carcinoma in situ and reduction of breast cancer incidence in women at high risk.1 It carries a boxed warning for women with ductal carcinoma in situ and women at high risk for breast cancer, naming uterine malignancies, stroke and pulmonary embolism.1

The WADA Prohibited List 2026 names tamoxifen among the anti-estrogenic substances in class S4.2, under hormone and metabolic modulators, in the section prohibited at all times, in and out of competition.10 The list states that prohibited substances in classes S4.1 and S4.2 are Specified Substances.10

9

Storage and handling

Sources in this part

  1. 1Mayne Pharma, 2022

The Mayne Pharma label for the tablets lists storage at 20 to 25 C (68 to 77 F), in a well-closed, light-resistant container as defined in the USP.1

10

What is not known

The label states that the effects of age, gender and race on the pharmacokinetics of tamoxifen have not been determined, and describes its excretion study as being in women.1 The label gives no oral bioavailability figure for tamoxifen, so the app's 95% has no figure from the label beside it.1 Wibowo and colleagues write that "Long-term studies that rigorously document the side-effect profile of tamoxifen in men are lacking".4

What is the half-life of tamoxifen?

The US label gives a terminal elimination half-life of about 5 to 7 days for tamoxifen.1 The app's figure is about 14 days (336 hours), which matches the label's figure of approximately 14 days for the metabolite N-desmethyl tamoxifen.1

Is Nolvadex the same as tamoxifen?

Nolvadex is a tamoxifen product, and the ATLAS trial describes its tamoxifen regimen as almost always Nolvadex 20 mg per day.2

Is tamoxifen banned by WADA?

Yes, under the World Anti-Doping Code: the WADA Prohibited List 2026 names tamoxifen among the anti-estrogenic substances in class S4.2, which is prohibited at all times, in and out of competition.10

What is the bioavailability of tamoxifen?

The app's figure is 95%, and the label gives no oral bioavailability figure.1

What did tamoxifen do to LH, FSH and testosterone in men?

In 10 healthy men given tamoxifen for 2 weeks at each of two doses, LH, FSH and testosterone concentrations rose significantly.6 In a retrospective study of 120 infertile men with idiopathic oligozoospermia on 20 mg daily for 6 months, the FSH, luteinizing hormone and testosterone levels were also significantly increased.7

Does tamoxifen change SHBG and IGF-I?

In the Birzniece study of 10 healthy men, tamoxifen at the higher dose increased SHBG by 20±7% (P<0.05) and reduced IGF-I by 25±6% (P<0.01), and raloxifene did not.6

What side effects did the NSABP P-1 trial report?

Compared with placebo, the label reports 33 versus 14 invasive endometrial cancers, 18 versus 6 pulmonary embolism cases and 34 versus 24 strokes on tamoxifen (stroke RR 1.42, 95% CI 0.82 to 2.51, a non-statistically significant increase in the label's words).1 The label also states that there was no impact of tamoxifen on overall or breast cancer-related mortality in that study.1

Has tamoxifen been studied after anabolic steroid use?

A 2014 review by Rahnema and colleagues of hypogonadal men with a history of anabolic-androgenic steroid use lists selective estrogen receptor modulators among management strategies, and reports that it was intended as a meta-analysis but no quality studies met the inclusion criteria. Its summary does not say which studies or drugs were screened, so it does not show whether tamoxifen was among them.5

Has tamoxifen been studied for male infertility?

Yes, a 2025 systematic review and meta-analysis by Khashaba and colleagues included ten randomised trials of clomiphene or tamoxifen, and concluded that the effect on the pregnancy rate remains uncertain.9 No meta-analysis could be calculated for pregnancy rates in tamoxifen versus placebo groups.9

13

References

  1. Mayne Pharma. TAMOXIFEN CITRATE tablet, film coated: prescribing information. DailyMed, US National Library of Medicine, label revision 08/2022. DailyMed label
  2. Davies C, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 2013. PMC3596060
  3. Fisher B, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998. PMID 9747868
  4. Wibowo E, et al. Tamoxifen in men: a review of adverse events. Andrology 2016. PMID 27152880
  5. Rahnema CD, et al. Anabolic steroid-induced hypogonadism: diagnosis and treatment. Fertil Steril 2014. PMID 24636400
  6. Birzniece V, et al. Neuroendocrine regulation of growth hormone and androgen axes by selective estrogen receptor modulators in healthy men. J Clin Endocrinol Metab 2010. PMID 20843951
  7. Kadioglu TC. Oral tamoxifen citrate treatment is more effective in normogonadotropic patients who have follicle-stimulating hormone levels within the lower half of normal. Int Urol Nephrol 2009. PMID 19381855
  8. Early Breast Cancer Trialists' Collaborative Group (Davies C, et al.). Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 2011. PMC3163848
  9. Khashaba S, et al. Efficacy of clomiphene citrate and tamoxifen on pregnancy rates in idiopathic male subfertility: a systematic review and meta-analysis. Asian J Urol 2025. PMID 39990067
  10. World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. WADA Prohibited List 2026